<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treprostinil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treprostinil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Treprostinil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10207" href="/d/html/10207.html" rel="external">see "Treprostinil: Drug information"</a> and <a class="drug drug_patient" data-topicid="11340" href="/d/html/11340.html" rel="external">see "Treprostinil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F230363"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Orenitram;</li>
<li>Orenitram Month 1;</li>
<li>Orenitram Month 2;</li>
<li>Orenitram Month 3;</li>
<li>Remodulin;</li>
<li>Tyvaso;</li>
<li>Tyvaso DPI Maintenance Kit;</li>
<li>Tyvaso DPI Titration Kit;</li>
<li>Tyvaso Refill;</li>
<li>Tyvaso Starter</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868486"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Remodulin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1040382"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Prostacyclin</span>;</li>
<li>
<span class="list-set-name">Prostaglandin</span>;</li>
<li>
<span class="list-set-name">Vasodilator</span></li></ul></div>
<div class="block dop drugH1Div" id="F57994207"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Doses are expressed in units of nanograms/kg/minute. A clinician with expertise in pulmonary arterial hypertension should be consulted for all management decisions.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents &gt;16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>New to prostacyclin therapy:</i> Continuous IV or SUBQ infusion: Initial: 1.25 nanogram/kg/minute; if dose cannot be tolerated, reduce to 0.625 nanogram/kg/minute. Increase dose in increments of 1.25 nanogram/kg/minute per week for first 4 weeks, followed by increments of 2.5 nanogram/kg/minute per week for remainder of therapy; may increase dose more often if tolerated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Discontinuation of therapy:</i> Avoid abrupt withdrawal. If infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require retitration. All patients should have access to back-up medication and infusion pumps.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight changes after initiation of therapy:</i> Due to the narrow therapeutic range, patient weight changes can significantly affect the dosage adjustment of treprostinil. Based on experience in adults, some experts recommend using the patient's baseline weight for treprostinil dosing, and only adjust by the actual body weight when variation in weight is ≥10 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from epoprostenol to treprostinil (see table):</i> Transition should occur in a hospital setting to monitor response. Transition is accomplished by initiating the infusion of treprostinil and increasing the treprostinil dose, while simultaneously reducing the dose of IV epoprostenol. During transition, increases in pulmonary arterial hypertension symptoms should be first treated with an increase in treprostinil dose. Occurrence of prostacyclin-associated adverse effects should be treated by decreasing the dose of epoprostenol.</p>
<p style="text-indent:-2em;margin-left:8em;">In the following step-wise approach, the starting epoprostenol dose is defined as the dose the patient was receiving at the beginning of the conversion to treprostinil.<b></b></p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>Transitioning From IV Epoprostenol to SUBQ or IV Treprostinil (Continuous Infusion)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Step</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Epoprostenol Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Treprostinil Dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">1</p></td>
<td align="left">
<p style="text-indent:0em;">Maintain current dose</p></td>
<td align="left">
<p style="text-indent:0em;">Initiate at 10% current epoprostenol dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">2</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 80% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 30% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 60% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 50% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 40% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 70% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">5</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 20% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 90% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">6</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 5% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 110% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue epoprostenol</p></td>
<td align="left">
<p style="text-indent:0em;">Maintain current dose and increase by 5% to 10% as needed</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57994211"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents &gt;16 years: Continuous IV or SUBQ infusion: No dosage adjustment necessary. Treprostinil is not cleared by dialysis.</p></div>
<div class="block dohp drugH1Div" id="F57994212"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents &gt;16 years: Continuous IV or SUBQ infusion:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Initial: 0.625 nanogram/kg/minute (ideal body weight). Hepatic impairment increases systemic exposure to treprostinil; use with caution and titrate slowly.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution and titrate slowly.</p></div>
<div class="block doa drugH1Div" id="F230365"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10207" href="/d/html/10207.html" rel="external">see "Treprostinil: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, cardiopulmonary comorbidities, and response to other agents. Parenteral prostacyclin analogues are generally reserved for initial therapy in high-risk patients or used as adjunctive therapy in patients who continue to deteriorate on oral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dry powder inhaler:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 16 mcg per treatment session inhaled 4 times per day approximately every 4 hours while patient is awake.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance: If tolerated, increase each inhaled dose by an additional 16 mcg per treatment session at approximately 1- to 2-week intervals; target dose: 48 to 64 mcg inhaled per session; continue at highest dose tolerated if adverse effects preclude titration.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Solution for inhalation: </b></p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 18 mcg (3 inhalations) 4 times per day administered every 4 hours while patient is awake; if 3 inhalations are not tolerated, reduce to 1 to 2 inhalations, then increase to 3 inhalations as tolerated.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance: If tolerated, increase each dose by 3 inhalations at approximately 1- to 2-week intervals; studies establishing effectiveness used a target dose of 54 mcg (9 inhalations) 4 times per day.</p>
<p style="text-indent:-2em;margin-left:8em;">The following regimens provide similar exposure:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Conversion from Treprostinil Solution for Inhalation to Dry Powder Inhaler</b></caption>
<colgroup><col align="center"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treprostinil solution: Number of breaths (total dose)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treprostinil dry powder inhaler (cartridge strength)</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;">≤5 breaths (≤30 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">16 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6 to 7 breaths (36 to 42 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">32 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 10 breaths (48 to 60 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">48 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to 12 breaths (66 to 72 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">64 mcg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.125 mg every 8 hours to 0.25 mg every 12 hours; dosing every 8 hours is generally preferred to improve tolerability (especially in patients with hypotension, low tolerance for side effects, or &lt;60 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27469018','lexi-content-ref-28680576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27469018','lexi-content-ref-28680576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Titration and maintenance: Increase dose in increments of 0.125 mg every 8 hours, or by 0.25 mg or 0.5 mg every 12 hours, no more frequently than every 3 to 4 days as tolerated to achieve optimal clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27469018','lexi-content-ref-28680576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27469018','lexi-content-ref-28680576'])">Ref</a></span>). Maximum dose is determined by tolerability; some experts recommend a target dose of 4 mg 3 times daily at 3 months, 6 mg 3 times daily at 6 months, and 8 mg 3 times daily at 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28680576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28680576'])">Ref</a></span>). If intolerable adverse effects occur, decrease dose in increments of 0.125 mg every 8 hours <b>or</b> 0.25 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Discontinuation of therapy: </i>Reduce the total daily dose in increments of 0.5 to 1 mg per day until discontinued; avoid abrupt discontinuation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed doses:</i> If a dose is missed, take the missed dose as soon as possible. If ≥2 doses are missed, restart at a lower dose and re-titrate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from injection to oral dosing:</i> Decrease the dose of parenteral treprostinil up to 30 <b>ng</b>/kg/minute per day, while simultaneously increasing the dose of oral treprostinil up to 2 mg every 8 hours as tolerated. <b>Note:</b> Consider transition to oral therapy in patients who are stable and more likely to tolerate the transition (eg, WHO Functional Class I or II patients).</p>
<p style="text-indent:-2em;margin-left:8em;">To estimate a comparable total daily dose of oral treprostinil, use the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Treprostinil oral total daily dose (mg) = Parenteral treprostinil dose (<b>ng</b>/kg/minute) x weight (kg) x 0.0072</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Some experts suggest ~1 mg of oral treprostinil administered every 8 hours is similar to 6 <b>ng</b>/kg/minute of IV treprostinil infusion in a 70 kg person (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27469018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27469018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment for concomitant therapy</i>: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Planned short-term interruption in oral treatment:</i> If patients are unable to continue oral treatment, a temporary infusion of parenteral treprostinil may be considered, using the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Total daily dose of parenteral treprostinil (<b>ng</b>/kg/minute) = (Oral total daily dose [mg] x 139) / patient weight (kg)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ or IV continuous infusion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>New to prostacyclin therapy:</i> Initial: 1.25 <b>ng</b>/kg/minute; if dose cannot be tolerated, reduce to 0.625 <b>ng</b>/kg/minute. Increase dose in increments of 1.25 <b>ng</b>/kg/minute per week for first 4 weeks, followed by increments of 2.5 <b>ng</b>/kg/minute per week for remainder of therapy; may increase dose more often if tolerated. The optimal dose varies; target dose is generally 40 to 80 <b>ng</b>/kg/minute, but can be higher based on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24048608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24048608'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Discontinuation of therapy:</i> Avoid abrupt withdrawal. If infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require re-titration.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight changes after initiation of therapy:</i> Due to the narrow therapeutic range, patient weight changes can significantly affect the dosage adjustment of treprostinil. Some experts recommend using the patient's baseline weight for treprostinil dosing, and only adjust by the actual body weight when variation in weight is ≥10 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>Transitioning from epoprostenol to treprostinil (see table):</i>
<b> Note:</b> Transition should occur in a hospital setting to monitor response. Transition is accomplished by initiating the infusion of treprostinil, and increasing the treprostinil dose, while simultaneously reducing the dose of intravenous epoprostenol. During transition, increases in PAH symptoms should be first treated with an increase in treprostinil dose. Occurrence of prostacyclin associated adverse effects should be treated by decreasing the dose of epoprostenol.</p>
<p style="text-indent:-2em;margin-left:6em;">In the following step-wise approach, the starting epoprostenol dose is defined as the dose the patient was receiving at the beginning of the conversion to treprostinil.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Transitioning from IV Epoprostenol to SUBQ or IV Treprostinil</b></caption>
<colgroup><col align="center"/>
<col/>
<col/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Step</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Epoprostenol Dose</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treprostinil Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;">1</p></td>
<td align="left">
<p style="text-indent:0em;">Maintain current dose</p></td>
<td align="left">
<p style="text-indent:0em;">Initiate at 10% current epoprostenol dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 80% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 30% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 60% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 50% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 40% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 70% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 20% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 90% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="left">
<p style="text-indent:0em;">Decrease to 5% of starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to 110% of starting epoprostenol dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue epoprostenol</p></td>
<td align="left">
<p style="text-indent:0em;">Maintain current dose and increase by 5% to 10% as needed</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0bed2607-230a-42d4-bec3-833ad998fbf9">Pulmonary hypertension associated with interstitial lung disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension associated with interstitial lung disease: Inhalation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dry powder inhaler:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 16 mcg per treatment session inhaled 4 times per day approximately every 4 hours while patient is awake.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: If tolerated, increase each inhaled dose by an additional 16 mcg per treatment session at approximately 1- to 2-week intervals; target dose: 48 to 64 mcg inhaled per session; continue at highest dose tolerated if adverse effects preclude titration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Solution for inhalation: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 18 mcg (3 inhalations) 4 times per day administered every 4 hours while patient is awake; if 3 inhalations are not tolerated, reduce to 1 to 2 inhalations, then increase to 3 inhalations as tolerated.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: If tolerated, increase each dose by 3 inhalations at ~1- to 2-week intervals; studies establishing effectiveness used a target dose of 72 mcg (12 inhalations) 4 times per day.</p>
<p style="text-indent:-2em;margin-left:6em;">The following regimens provide similar exposure:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Conversion from Treprostinil Solution for Inhalation to Dry Powder Inhaler</b></caption>
<colgroup><col align="center"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treprostinil solution: Number of breaths (total dose)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treprostinil dry powder inhaler (cartridge strength)</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;">≤5 breaths (≤30 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">16 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6 to 7 breaths (36 to 42 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">32 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 10 breaths (48 to 60 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">48 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to 12 breaths (66 to 72 mcg)</p></td>
<td align="left">
<p style="text-indent:0em;">64 mcg</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991038"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV or SUBQ continuous infusion:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhalation, Oral:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Treprostinil is not removed by dialysis.</p></div>
<div class="block doha drugH1Div" id="F50988267"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhalation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling. However, hepatic impairment increases systemic exposure to treprostinil. Use with caution and titrate slowly.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ or IV continuous infusion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Initial: 0.625 <b>ng</b>/kg/minute. Hepatic impairment increases systemic exposure to treprostinil; use with caution and titrate slowly.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution and titrate slowly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): Initial: 0.125 mg every 12 hours; increase in increments of 0.125 mg every 12 hours no more frequently than every 3 to 4 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B): Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F230336"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (oral, oral inhalation: 15% to 45%), vasodilation (SUBQ: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (SUBQ: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (oral: 30% to 69%; SUBQ: 25%), nausea (oral, oral inhalation, SUBQ: 19% to 40%), upper abdominal pain (oral: 5% to 12%), vomiting (oral: 17% to 36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Severe infusion-related reaction (SUBQ: 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site pain (SUBQ: 85%; severe: 39%), infusion-site reaction (including erythema, induration, skin rash: SUBQ: 83%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (oral: 63% to 75%; oral inhalation: 41%; SUBQ: 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Jaw pain (oral, SUBQ: 11% to 18%), limb pain (oral: 14% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (oral inhalation: 54%), pharyngolaryngeal pain (oral inhalation: ≤25%), throat irritation (oral inhalation: ≤25%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (SUBQ: 9%), hypotension (SUBQ: 4%), syncope (oral inhalation: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (oral: 4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (oral: 6% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet aggregation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hemoptysis (oral inhalation), nasal discomfort (oral inhalation)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, maculopapular rash, papular rash, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia, ostealgia</p></div>
<div class="block coi drugH1Div" id="F230348"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection/Inhalation: There are no contraindications listed in the US manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to treprostinil or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F230334"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: May inhibit platelet aggregation and increases the risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Acute bronchospasm may occur when administered via inhalation; use with caution in patients with bronchial hyperreactivity (eg, asthma, chronic obstructive pulmonary disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May produce symptomatic hypotension; use with caution in patients with low systemic arterial blood pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rebound pulmonary hypertension: Abrupt withdrawal/large dosage reductions may worsen symptoms of PAH. If a SUBQ or IV infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require retitration. Regardless of administration route (inhalation, IV, oral, SUBQ), treatment interruptions should be avoided. Immediate access to medication, back-up inhalation device, or pump and infusion sets is essential to prevent treatment interruptions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">- IV/SUBQ: Dose reduction is recommended for the initial dose in patients with mild to moderate hepatic insufficiency; titrate dose slowly in patients with hepatic insufficiency; has not been studied in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">- Oral: Dose reduction is recommended for patients with mild hepatic impairment. Avoid use in patients with moderate impairment; use is contraindicated in patients with severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Tablets should not be administered with ethanol because the release of treprostinil from the tablet may occur at a faster rate than intended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form related issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tablet: Tablet shell does not dissolve and is eliminated in the feces as an insoluble shell; in patients with diverticulosis, tablet can lodge in a diverticulum.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Chronic continuous IV infusion of treprostinil using an external infusion pump via a chronic indwelling central venous catheter has been associated with serious blood stream infections. This method of administration should be reserved for patients who are intolerant of the SUBQ route or in whom the benefit outweighs the potential risks. Clinicians should routinely review with patient the importance of infection control practices for the management of a central venous catheter. The use of an implantable IV infusion pump may have a lower risk of blood stream infections compared to the use of an external IV infusion pump.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Treprostinil injection should only be used by clinicians experienced in the treatment of PAH. Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil, either as an IV/SUBQ infusion or inhalation, and care for the infusion system/inhalation device. Initiation of infusion must occur in a setting where adequate personnel and equipment necessary for hemodynamic monitoring and emergency treatment are available.</p></div>
<div class="block foc drugH1Div" id="F230343"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tyvaso DPI Maintenance Kit: 16 mcg (112 ea); 32 mcg (112 ea); 48 mcg (112 ea); 64 mcg (112 ea); 112 x 32MCG &amp; 112 x48MCG (224 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tyvaso DPI Titration Kit: 16 &amp; 32 &amp; 48 MCG (252 ea); 112 x 16MCG &amp; 84 x 32MCG (196 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tyvaso: 0.6 mg/mL (2.9 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tyvaso Refill: 0.6 mg/mL (2.9 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tyvaso Starter: 0.6 mg/mL (2.9 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remodulin: 20 mg/20 mL (20 mL); 50 mg/20 mL (20 mL); 100 mg/20 mL (20 mL); 200 mg/20 mL (20 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/20 mL (20 mL); 50 mg/20 mL (20 mL); 100 mg/20 mL (20 mL); 200 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orenitram: 0.125 mg, 0.25 mg, 1 mg, 2.5 mg, 5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orenitram Month 1: 0.125 mg (126s) and 0.25 mg (42s) (168 ea) [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orenitram Month 2: 0.125 (126s) and 0.25 mg (210s) (336 ea) [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orenitram Month 3: 0.125 mg (126s), 0.25 mg (42s), and 1 mg (84s) (252 ea) [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p></div>
<div class="block geq drugH1Div" id="F230331"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16324023"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Tyvaso DPI Maintenance Kit Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mcg (per each): $246.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32 mcg (per each): $246.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">48 mcg (per each): $246.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">64 mcg (per each): $246.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Tyvaso DPI Titration Kit Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 &amp; 32 &amp; 48 mcg (per each): $109.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 x 16MCG &amp;84 x 32MCG (per each): $140.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Remodulin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/20 mL (per mL): $76.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/20 mL (per mL): $191.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/20 mL (per mL): $382.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $763.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Treprostinil Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/20 mL (per mL): $68.76 - $72.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/20 mL (per mL): $171.90 - $181.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/20 mL (per mL): $343.80 - $362.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $687.59 - $725.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tyvaso Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/mL (per mL): $308.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tyvaso Refill Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/mL (per mL): $308.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tyvaso Starter Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/mL (per mL): $344.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Extended Release Therapy Pack</b> (Orenitram Month 1 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 &amp; 0.25 mg (per each): $10.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Extended Release Therapy Pack</b> (Orenitram Month 2 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 &amp; 0.25 mg (per each): $13.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Extended Release Therapy Pack</b> (Orenitram Month 3 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 &amp; 0.25 &amp;1 mg (per each): $29.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Orenitram Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $8.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $16.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $66.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $166.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $333.31</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868487"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remodulin: 1 mg/mL (20 mL); 2.5 mg/mL (20 mL); 5 mg/mL (20 mL); 10 mg/mL (20 mL) [contains metacresol, sodium chloride, sodium citrate]</p></div>
<div class="block admp drugH1Div" id="F57994214"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Avoid treatment interruptions or rapid large dosage reductions. Immediate access to medication, a back-up pump, and infusion sets are essential to prevent treatment interruptions.</p>
<p style="text-indent:-2em;margin-left:2em;">Adolescents &gt;16 years: Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous IV infusion:</i> IV use is recommended when SUBQ infusion is not tolerated or when the benefit outweighs the potential risks of an indwelling central venous catheter. Administer by continuous infusion using a central indwelling catheter and an external infusion pump. The ambulatory infusion pump should have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have ±6% or better accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Peripheral infusion may be used temporarily until central line is established. IV infusion sets with an in-line 0.22- or 0.2-micron filter should be used for central and peripheral administration. If transitioning from the use of an external infusion pump to an implantable IV infusion pump (eg, Implantable System for Remodulin), refer to the pump manufacturer's manual for instructions regarding preparation, programming, implantation, and refilling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous SUBQ infusion:</i> Administer undiluted via continuous SUBQ infusion using an appropriately designed infusion pump. The ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates in ~0.002 mL/hour increments; have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have ±6% or better accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Based on experience in adults, proactively manage infusion-site reactions based on individual patient needs and by combining multiple strategies, including improved dosing strategies (eg, more rapid dose escalation), appropriate site selection, less frequent infusion site changes (eg, every 2 to 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17319903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17319903'])">Ref</a></span>)), and analgesic care (pharmacologic and nonpharmacologic) when pain occurs. Rotate infusion site when patient experiences continued site pain, itching, erythema, drainage, or bleeding; decreased site pain and need for site changes or discontinuation due to site pain may be reduced in patients who are managed proactively in this manner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20855220','lexi-content-ref-18698881','lexi-content-ref-24618545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20855220','lexi-content-ref-18698881','lexi-content-ref-24618545'])">Ref</a></span>). Abdominal fat is the most common site used, but other sites used include hips, thighs, and underarms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22806762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22806762'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F230345"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Avoid treatment interruptions or rapid large dosage reductions with use of inhalation, IV, or SUBQ formulations. Immediate access to medication, a back-up inhalation device, or pump and infusion sets is essential to prevent treatment interruptions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dry powder inhalation:</b> For inhalation only with the Tyvaso DPI inhaler. Administer using a single inhalation per cartridge; if prescribed dose is &gt;64 mcg per treatment session, more than one cartridge will be needed per session. If refrigerated, allow blister strips and inhaler to warm to room temperature for 10 minutes prior to use. In between use, store inhaler with the mouthpiece attached and empty. Wipe outside of inhaler with a clean, dry cloth only, if needed; do not rinse or wash inhaler (always keep inhaler dry). Discard inhaler after 7 days of use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Solution for inhalation:</b> For inhalation only via the Tyvaso Inhalation System; do not mix with other medications; inhalation solution is not for oral ingestion. Prior to the first treatment session of each day, transfer the entire contents of one ampule (undiluted) into the medicine chamber; one ampule contains sufficient volume of medication for all 4 treatment sessions in a single day. Each treatment session will take 2 to 3 minutes; between each session, the device should be capped and stored upright with the remaining medication inside. At the end of each day, the medicine chamber and any remaining medication must be discarded. Clean inhalation device chamber with a dry cloth once a week; clean device accessories daily (after last treatment session) with mild, soapy, warm water, rinse and air dry. Avoid skin or eye contact; wash hands after handling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> IV use is recommended when SUBQ infusion is not tolerated or when the benefit outweighs the potential risks of an indwelling central venous catheter. Administer by continuous infusion using a central indwelling catheter and an external infusion pump. The ambulatory infusion pump should have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have ± 6% accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Peripheral infusion may be used temporarily until central line is established. IV infusion sets with an in-line 0.22- or 0.2-micron filter should be used for central and peripheral administration. If transitioning from the use of an external infusion pump to an implantable IV infusion pump (eg, Implantable System for Remodulin), refer to the pump manufacturer's manual for instructions regarding preparation, programming, implantation, and refilling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food (minimum of 250 calories containing 30% to 50% fat) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23927483','lexi-content-ref-26869810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23927483','lexi-content-ref-26869810'])">Ref</a></span>); 3 times daily dosing is less dependent on food intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28680576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28680576'])">Ref</a></span>). Swallow tablets whole; do not crush, split or chew; use only intact tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Inhaled and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate and long-term postoperative period for the theoretical circumstance of reduced absorption after bariatric surgery. Abrupt discontinuation (or loss of absorption) may lead to worsening of pulmonary hypertension symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ infusion:</b> Administer undiluted via continuous SUBQ infusion using an appropriately designed infusion pump. The ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates in ~0.002 mL/hour increments; have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have ± 6% accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Proactively manage infusion-site reactions based on individual patient needs and by combining multiple strategies, including improved dosing strategies (eg, more rapid dose escalation), appropriate site selection, less frequent infusion site changes (eg, every 2 to 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17319903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17319903'])">Ref</a></span>)), and analgesic care (pharmacologic and nonpharmacologic) when pain occurs. Rotate infusion site when patient experiences continued site pain, itching, erythema, drainage, or bleeding; decreased site pain and need for site changes or discontinuation due to site pain may be reduced in patients who are managed proactively in this manner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20855220','lexi-content-ref-18698881','lexi-content-ref-24618545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20855220','lexi-content-ref-18698881','lexi-content-ref-24618545'])">Ref</a></span>). Abdominal fat is the most common site used but other sites used include hips, thighs, and underarms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22806762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22806762'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F230359"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Dry powder inhaler:</p>
<p style="text-indent:-2em;margin-left:4em;">Inhaler device: Store at 2°C to 25°C (36°F to 77°F); excursions permitted. After initial use, the inhaler must be discarded and replaced with a new inhaler after 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Unopened blister cards or strips: Store at 2°C to 8°C (36°F to 46°F) or may store for up to 5 weeks at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Opened blister strips: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Do not return to the refrigerator; must be used within 3 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection solution: Store vials at 25°C (77°F); excursions are permitted between 2°C and 30°C (36°F and 86°F). Contents of a vial should not be used past 30 days after initial needle access into the vial. IV solutions prepared with Remodulin sterile diluent or similar approved high-pH glycine diluent (eg, Flolan sterile diluent) may be stored for 14 days at room temperature; solutions prepared with SWFI or NS may be stored for 4 hours at room temperature or 24 hours refrigerated. After dilution, may administer over a maximum of 48 hours at up to 40°C (104°F). See prescribing information for additional details.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution for inhalation: Store ampules in foil packs at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from light. Once foil pack is opened, ampules should be used within 7 days. Following transfer of solution to inhalation device, solution should remain in device for no more than 24 hours; discard unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F53569302"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1) in patients with New York Heart Association (NYHA) class II to IV symptoms to decrease exercise-associated symptoms; to diminish clinical deterioration when transitioning from epoprostenol (Remodulin: FDA approved in ages &gt;16 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Treatment of PAH (WHO group 1) in patients with NYHA class III symptoms to improve exercise ability; treatment of pulmonary hypertension associated with interstitial lung disease (WHO group 3) to improve exercise ability (Tyvaso: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of PAH (WHO group 1) in patients with WHO functional class II to III symptoms to delay disease progression and to improve exercise capacity or PAH associated with connective tissue disease (Orenitram: FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F13300164"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (major), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F230338"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Treprostinil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Treprostinil. Management: Reduce the initial treprostinil extended release tablet dose to 0.125 mg twice daily, titrating by 0.125 mg twice daily every 3 to 4 days. No preemptive dose adjustment is recommended for other treprostinil products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F230350"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Information related to the use of treprostinil for the treatment of pulmonary arterial hypertension (PAH) in pregnant patients is limited (Lim 2019; Luo 2020; Rosengarten 2015; Smith 2012; Xiang 2018; Zhang 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Untreated PAH in pregnancy increases the risk for maternal heart failure, stroke, preterm delivery, low birth weight, and maternal/fetal death. Patients with PAH are encouraged to avoid becoming pregnant. When treatment is needed, agents with more information may be preferred for use in pregnant patients (ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53569301"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, dyspnea, fatigue, activity tolerance, symptoms of excessive dose (eg, headache, nausea, vomiting), infusion-site reactions (pain, bleeding/bruising, erythema, induration, or rash), CBC.</p></div>
<div class="block pha drugH1Div" id="F230333"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Treprostinil is a direct vasodilator of both pulmonary and systemic arterial vascular beds; also inhibits platelet aggregation.</p></div>
<div class="block phk drugH1Div" id="F230347"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Affected by food; AUC<sub>inf</sub> increased by 49% when administered following a high-fat, high-calorie meal compared to fasting conditions. Relative bioavailability following oral administration of 1 mg is not significantly altered by meals ranging from 250 to 500 calories.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Rapidly and completely.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 14 L/70 kg ideal body weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 91% to 96%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (primarily by CYP2C8); forms 5 inactive metabolites (HU1-HU5).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Inhalation solution: 64% to 72% (dose-dependent); SUBQ: 100%; Oral: ~17%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: Dry powder inhaler: 27 to 50 minutes; SUBQ: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Dry powder inhaler: Median: ~10 minutes; Inhalation solution: ~7 to 15 minutes; Oral: 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Urine (79%; 4% as unchanged drug, 64% as metabolites); feces (13%).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Urine (0.19% as unchanged drug); feces (1.13% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51204331"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Cl reduced up to 80% in patients with hepatic impairment. C<sub>max</sub> increased 2-fold in patients with mild impairment; 4-fold in patients with moderate impairment; and 5-fold in patients with severe impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4301443"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Trepulmix | Trisuva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil orpha</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Timeraxone | Tyvaso</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Trepulmix | Tresuvi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil beta | Treprostinil Tillomed | Trepulmix | Tresuvi</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Treprostinilo dr. reddys | Treprostinilo Ferrer | Trepulmix | Tresuvi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treposa | Treprostinil Tillomed</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil Reddy | Treprostinil Tillomed</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Treprostinil | Trepulmix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Tresuvi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Treposuvi</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil dr reddys | Trepulmix | Tresuvi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Treprost</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil Tillomed</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trepulmix</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treposuvi | Trepulmix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tresuvi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Trepulmix | Tresuvi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Tresuvi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil Tillomed | Tresuvi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Remodulin | Treprostinil amomed</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tresuvi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Remodulin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22806762">
<a name="22806762"></a>Bishop BM, Mauro VF, Khouri SJ. Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. <i>Pharmacotherapy</i>. 2012;32(9):838-855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/22806762/pubmed" id="22806762" target="_blank">22806762</a>]</span>
<span class="doi">10.1002/j.1875-9114.2012.01114.x</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332729">
<a name="17332729"></a>Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - Seven Sites, United States, 2003-2006. <i>MMWR Morb Mortal Wkly Rep. </i>2007;56(8):170-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/17332729/pubmed" id="17332729" target="_blank">17332729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27469018">
<a name="27469018"></a>Chakinala MM, Feldman JP, Rischard F, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. <i>J Heart Lung Transplant</i>. 2017;36(2):193-201. doi: 10.1016/j.healun.2016.06.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/27469018/pubmed" id="27469018" target="_blank">27469018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24048608">
<a name="24048608"></a>Coons JC, Clarke M, Wanek MR, Bauer A, Bream-Rouwenhorst HR. Safe and effective use of prostacyclins to treat pulmonary arterial hypertension. <i>Am J Health Syst Pharm</i>. 2013;70(19):1716-1723. doi: 10.2146/ajhp130005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/24048608/pubmed" id="24048608" target="_blank">24048608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12716139">
<a name="12716139"></a>Gildea TR, Arroliga AC, Minai OA. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. <i>Cleve Clin J Med.</i> 2003;70(suppl 1):18-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/12716139/pubmed" id="12716139" target="_blank">12716139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16151039">
<a name="16151039"></a>Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. <i>Am J Respir Crit Care Med.</i> 2005;172(12):1586-1589.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/16151039/pubmed" id="16151039" target="_blank">16151039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J</i>. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST Guideline and Expert Panel Report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16778286">
<a name="16778286"></a>Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. <i>Chest. </i>2006;129(6):1636-1643.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/16778286/pubmed" id="16778286" target="_blank">16778286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23927483">
<a name="23927483"></a>Lim A, Wang-Smith L, Kates J, Laurent A, Kumar P, Laliberte K. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers. <i>J Clin Pharm Ther</i>. 2013;38(6):450-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/23927483/pubmed" id="23927483" target="_blank">23927483</a>]</span>
<span class="doi">10.1111/jcpt.12085</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31074218">
<a name="31074218"></a>Lim K, Chang SA, Oh SY, et al. Pulmonary arterial hypertension and pregnancy: single center experience in current era of targeted therapy. <i>Korean Circ J</i>. 2019;49(6):545-554. doi: 10.4070/kcj.2018.0350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/31074218/pubmed" id="31074218" target="_blank">31074218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32501975">
<a name="32501975"></a>Luo J, Shi H, Xu L, Su W, Li J. Pregnancy outcomes in patients with pulmonary arterial hypertension: a retrospective study. <i>Medicine (Baltimore)</i>. 2020;99(23):e20285. doi:10.1097/MD.0000000000020285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/32501975/pubmed" id="32501975" target="_blank">32501975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855220">
<a name="20855220"></a>Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. <i>J Heart Lung Transplant</i>. 2010;29(11):1210-1217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/20855220/pubmed" id="20855220" target="_blank">20855220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in collaboration with the American College of Chest Physicians; American Thoracic Society Inc; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol.</i> 2009;53(17):1573–1619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12548091">
<a name="12548091"></a>McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. <i>J Cardiovasc Pharmacol.</i> 2003;41(2):293-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/12548091/pubmed" id="12548091" target="_blank">12548091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orenitram.1">
<a name="Orenitram.1"></a>Orenitram (treprostinil) extended-release tablets [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26869810">
<a name="26869810"></a>Pugliese SC, Bull TM. Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension. <i>Integr Blood Press Control</i>. 2016;9:1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/26869810/pubmed" id="26869810" target="_blank">26869810</a>]</span>
<span class="doi">10.2147/IBPC.S68230</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28483121">
<a name="28483121"></a>Raeisi-Giglou P, Wang XF, Dakkak W, Bair N, Dweik RA, Tonelli AR. Effect of weight on parenteral prostacyclin analogues dosing in pulmonary hypertension. <i>Chest</i>. 2017;151(5):1189-1192. doi: 10.1016/j.chest.2017.01.043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/28483121/pubmed" id="28483121" target="_blank">28483121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28680576">
<a name="28680576"></a>Rahaghi FF, Feldman JP, Allen RP, et al. Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. <i>Pulm Circ</i>. 2017;7(1):167-174. doi: 10.1086/690109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/28680576/pubmed" id="28680576" target="_blank">28680576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Remodulin.1">
<a name="Remodulin.1"></a>Remodulin (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RemodulinCAN.1">
<a name="RemodulinCAN.1"></a>Remodulin (treprostinil) [product monograph]. Magog, QC, Canada: Unither Biotech; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26152021">
<a name="26152021"></a>Rosengarten D, Kramer R. Pregnancy in a woman with pulmonary hypertension: favorable outcome with intravenous treprostinil. <i>Clin Exp Obstet Gynecol</i>. 2015;42(3):390-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/26152021/pubmed" id="26152021" target="_blank">26152021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17400684">
<a name="17400684"></a>Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary Arterial hypertension. <i>Chest.</i> 2007;132(3):757-763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/17400684/pubmed" id="17400684" target="_blank">17400684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17319903">
<a name="17319903"></a>Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. <i>J Thromb Haemost</i>. 2007;5(3):483-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/17319903/pubmed" id="17319903" target="_blank">17319903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18698881">
<a name="18698881"></a>Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. <i>Clin Pharmacokinet</i>. 2008;47(9):611-618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/18698881/pubmed" id="18698881" target="_blank">18698881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139549">
<a name="22139549"></a>Smith JS, Mueller J, Daniels CJ. Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach. <i>Lung</i>. 2012;190(2):155-60. doi: 10.1007/s00408-011-9345-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/22139549/pubmed" id="22139549" target="_blank">22139549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24937180">
<a name="24937180"></a>Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/24937180/pubmed" id="24937180" target="_blank">24937180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tyvaso.1">
<a name="Tyvaso.1"></a>Tyvaso inhalation solution (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tyvaso.2">
<a name="Tyvaso.2"></a>Tyvaso DPI (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24618545">
<a name="24618545"></a>White RJ, Levin Y, Wessman K, Heininger A, Frutiger K. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. <i>Pulm Circ</i>. 2013;3(3):611-621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/24618545/pubmed" id="24618545" target="_blank">24618545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30095650">
<a name="30095650"></a>Xiang Y, Li J, Sun Y. A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy. <i>Medicine (Baltimore)</i>. 2018;97(32):e11810. doi: 10.1097/MD.0000000000011810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/30095650/pubmed" id="30095650" target="_blank">30095650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29525197">
<a name="29525197"></a>Zhang J, Lu J, Zhou X, et al. Perioperative management of pregnant women with idiopathic pulmonary arterial hypertension: an observational case series study from China.<i> J Cardiothorac Vasc Anesth</i>. 2018;32(6):2547-2559. doi: 10.1053/j.jvca.2018.01.043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treprostinil-pediatric-drug-information/abstract-text/29525197/pubmed" id="29525197" target="_blank">29525197</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141095 Version 34.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
